BiOZEEN, a niche bioprocess engineering organisation delivering end-to-end solutions to the biopharmaceutical sector across the globe, today announced the appointment of as the president and chief executive officer (CEO) of the company. He brings to board over 24 years of experience in healthcare and life sciences sector.

Previously, Mahadevan served as the global director and commercial leader with Merck Millipore where he led global market segment strategic initiatives. Dr Anil Paul Kariath speaking on behalf of the board of directors, BiOZEEN expressed his delight on having the versatile leader. He said, “BiOZEEN identified in Mahadevan a dynamic leader with clarity on visionary and operational skills, both from technology and geography perspective, making him the right match for us. In the past, Mahadevan has executed global strategies with his industry knowledge, strong networking skills and industrial contacts. I believe this will help him steer Biozeen to the next level.”

Mahadevan cites several opportunities for the industry and organisation, “Life Sciences and emerging markets is where the next wave of biotech growth is poised to occur. As a total solutions provider our business model integrates consulting, design and build equipments and training that would insure productivity and facilitate growth in the bio-pharmaceutical industry as we at BiOZEEN plan to be their unique partner.”

Started operations in the year 2006, BiOZEEN is a turnkey bioprocess engineering organisation delivering end-to-end solutions to the biopharmaceutical sector across the globe. Operational through a state-of-the-art facility sprawling over an area of eight acres in Bangalore, BiOZEEN undertakes bioprocess equipment manufacturing, consultancy services, manpower training and bioprocess research.